Scientists identify high chance of reinfection with Omicron subvariants for unvaccinated
Scientists have found a decrease in the ability of antibodies from a previous Omicron infection in unvaccinated people to neutralise the subvariants. Vaccinated people fared better.
Researchers at the African Health Research Institute have shown in laboratory testing of blood plasma that there is a good chance that people who were infected with the original Omicron variant in December 2021 or January 2022 can get it again this time round.
The Omicron variant first identified in December 2021 is known by scientists as BA.1. Since that variant was first identified South African scientists also identified two other subvariants, BA.4 and BA.5. The rise of these two subvariants has caused a considerable increase in new infections, that some argue might be the start of the country’s fifth wave, with daily positivity rates of more than 20% on normal business days.
Dr Richard Lessels, one of the leading scientists looking for new variants and studying the mutations on the Omicron variant, explained last week that BA.4 and BA.5 are grouped together because they have the same spike protein.
He said they are now thinking of Omicron as a family of different subvariants. BA.4 and BA.5 are most closely related to BA.2, another variant that caused a small bump in infections after schools resumed in January. The two subvariants have some mutations that are known to scientists and thought to be responsible for enhanced transmissibility and escaping the body’s immune system.
Not all of their other mutations are understood yet.
The National Institute for Communicable Diseases (NICD) monitors hospital admissions and Dr Waasila Jassat, who leads the monitoring and the surveillance teams, has reported an increase in hospital admissions in the past few weeks. Since the fourth wave in SA, however, there has been a decoupling between the rise in cases and the rise in people hospitalised and dying from severe disease.
BA.1 caused a very large outbreak of coronavirus infections in December 2021 and January 2022 in South Africa. At the time it was established that some of the mutations on the BA.1 variant allowed for it to escape immunity built up from prior infections with other SARS-CoV2 variants and vaccines or a combination of the two.
Prof Alex Sigal and Khadija Khan from the Africa Health Research Institute set out to test whether BA.4 and BA.5 will also reinfect people who have already had Covid-19. The institute has been on the forefront of gathering information about the SARS-CoV2 virus and, among other things, grew Omicron for the first time. A preprint of their paper, which has not been peer reviewed yet, was published last week.
For this work they used plasma, which is the component of blood that contains antibodies, from 24 unvaccinated and 15 vaccinated people. They found that neutralising antibodies were much less effective in fighting off BA.4 and BA.5 subvariants in the blood plasma of people who had prior infection than in those who had prior infections but were also vaccinated.
“The results also show that both the Pfizer and J&J vaccines enhance protection against the Omicron subvariants in people who were vaccinated and had a previous Omicron BA.1 infection,” a statement on the outcomes of their research read.
Sigal explained that the ability of the antibodies in the plasma to eliminate the viruses was compared in the different sets of people whose blood was tested.
They found that there is a 7.6-fold (BA.4) and 7.5-fold (BA.5) decrease in the ability of antibodies from a previous Omicron infection in unvaccinated people to neutralise the subvariants. Those who were vaccinated fared better: there was a 3.2-fold (BA.4) and 2.6-fold (BA.5) decrease, respectively. Ultimately, neutralisation levels were about five times higher for those who were vaccinated, compared with the unvaccinated group.
“BA.4/BA.5 escape, while not as dramatic as Omicron escape from vaccine or Delta immunity, is enough to lead to a new infection wave driven by the subvariants,” Sigal said. “This is consistent with current surveillance data coming out of South Africa. However, based on our results, it seems unlikely that these subvariants will cause much more severe disease than the previous wave. Our study again shows the protection offered by Covid-19 vaccines in maintaining levels of immunity that at the very least are effective at preventing severe disease.”
The NICD this week started releasing data on possible reinfections. On Wednesday, 4 May, there were 950 reinfections. On Tuesday, a day following a public holiday with a lower number of people testing, there were 553. On Monday, there were 45. DM168
This story first appeared in our weekly Daily Maverick 168 newspaper, which is available countrywide for R25.
"Information pertaining to Covid-19, vaccines, how to control the spread of the virus and potential treatments is ever-changing. Under the South African Disaster Management Act Regulation 11(5)(c) it is prohibited to publish information through any medium with the intention to deceive people on government measures to address COVID-19. We are therefore disabling the comment section on this article in order to protect both the commenting member and ourselves from potential liability. Should you have additional information that you think we should know, please email [email protected]"